ABVC BioPharma Secures $2.5 Million in International Investments to Fuel Growth

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company specializing in ophthalmology, CNS, and oncology/hematology, has announced a significant boost in its growth trajectory with over USD 2.5 million in private equity investments from international investors. This financial endorsement comes after a thorough evaluation of the Company's business model and operational strategies, highlighting a strong belief in ABVC's current initiatives and future plans.

The investment, characterized by a structured six-month lock-up period, not only provides ABVC with near-term operational flexibility but also reflects the growing confidence in its pipeline of therapeutic innovations. Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized the Company's commitment to real science and long-term value creation, stating, "We are building a company grounded in real science and long-term value. Our team is working tirelessly to translate the Company’s potential into real success."

This influx of capital is a testament to the validation of ABVC's product vision and the effectiveness of its leadership and strategic execution. With this solid foundation, ABVC is now poised to pursue additional partnerships and licensing opportunities to further advance its clinical programs and enhance shareholder value.

ABVC BioPharma's active pipeline includes six drugs and one medical device, ABV-1701/Vitargus®, under development. The Company leverages in-licensed technology from prestigious research institutions such as Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center to conduct proof-of-concept trials through Phase II of clinical development. For Vitargus®, ABVC plans to initiate pivotal clinical trials (Phase III) through global collaborations.

While the Company is optimistic about its future, it acknowledges the inherent risks and uncertainties in the biopharmaceutical industry, including challenges in manufacturing, financing, competition, and regulatory approvals. More detailed information on these risks is available in the Company's filings with the Securities and Exchange Commission (SEC), accessible at http://www.sec.gov.

This development marks a significant milestone for ABVC BioPharma as it continues to innovate and expand its footprint in the biopharmaceutical sector, promising potential advancements in treatment options for patients worldwide.